Home > Inhibitors & Agonists > PI3K/Akt/mTOR > mTOR
Cat. No. Product name CAS No.
DC11929 ME-344

A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.

1374524-68-1
DC11866 AZD 3147 Featured

A potent, selective dual mTORC1 and mTORC2 inhibitor with enzyme IC50 of 1.5 nM.

1101810-02-9
DC1001 FK-506 (Tacrolimus) Featured

Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.

104987-11-3
DC5084 AZD-8055 Featured

AZD-8055 is a potent, selective, and orally bioavailable ATP-competitive mTOR kinase inhibitor with an IC50 of 0.8 nM.

1009298-09-2
DC8377 CC-115 Featured

CC-115 is a dual inhibitor of DNA-dependent protein kinase (DNA-PK) and mammalian target of rapamycin (mTOR), with potential antineoplastic activity.

1228013-15-7
DC8497 CC-223 Featured

CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with >150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).

1228013-30-6
DC10125 CZ415 Featured

CZ415 is a potent and highly selective mTOR inhibitor.

1429639-50-8
DC1501 Everolimus Featured

Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM.

159351-69-6
DC7014 GPI-1046

For the detailed information of GPI-1046, the solubility of GPI-1046 in water, the solubility of GPI-1046 in DMSO, the solubility of GPI-1046 in PBS buffer, the animal experiment (test) of GPI-1046, the cell expriment (test) of GPI-1046, the in vivo, in vitro and clinical trial test of GPI-1046, the EC50, IC50,and Affinity of GPI-1046, Please contact DC Chemicals..

186452-09-5
DC11151 ICSN3250 hydrochloride

ICSN3250 (ICSN-3250) hydrochloride is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.

1561902-79-1
DC11150 ICSN3250

ICSN3250 (ICSN-3250) is a halitulin-analogue that acts as a new-class, specific mTOR inhibitor through a mechanism distinct from previous mTOR inhibitors.

1561902-73-5
DC7171 INK-128(Sapanisertib) Featured

INK 128 is a potent and selective mTOR inhibitor with IC50 of 1 nM; >200-fold less potent to class I PI3K isoforms.

1224844-38-5
DC3101 Ku-0063794

KU-0063794 is a potent and highly specific mTOR inhibitor for both mTORC1 and mTORC2 with IC50 ~10 nM.

938440-64-3
DC7210 LY-303511(Nv-128) Featured

LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.

154447-38-8
DC1006 OSI-027 Featured

OSI-027 is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, respectively.

936890-98-1
DC7482 Torkinib (PP242) Featured

PP242 is a selective mTOR inhibitor with IC50 of 8 nM; targets both mTOR complexes with >10- and 100-fold selectivity for mTOR than PI3Kδ or PI3Kα/β/γ, respectively; also showed slightly weaker activity against BRD4 (Kd= 1.7 uM).

1092351-67-1
DC11816 RapaLink-1 Featured

RapaLink-1 is a third-generation mTOR inhibitor that overcomes resistance to existing first- and second-generation inhibitors; blocks mTOR signaling of the F2108L mTOR and M2327I mTOR drug resistant mutants; RapaLink-1 is more potent mTOR inhibitor than rapamycin.

1887095-82-0
DC1048 Rapamycin (Sirolimus) Featured

Rapamycin (Sirolimus, AY-22989, WY-090217) is a specific mTOR inhibitor with IC50 of ~0.1 nM. -

53123-88-9
DC11306 Secorapamycin A(Seco Rapamycin) Featured

Seco-rapamycin(Secorapamycin A) is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR..

147438-27-5
DCAPI1488 Temsirolimus Featured

Temsirolimus is an inhibitor of ribosomal protein S6 phosphorylation and inhibits cell growth and clonogenic survival of cells in a concentration-dependent manner.

162635-04-3
DC3117 Torin2 Featured

Torin 2 is a highly potent and selective mTOR inhibitor with IC50 of 0.25 nM, and also exhibits potent cellular activity against ATM/ATR/DNA-PK with EC50 of 28 nM, 35 nM and 118 nM, respectively.

1223001-51-1
DC3118 Torin1 Featured

Torin1 is a potent inhibitor of mTOR with IC50 of 2-10 nM.

1222998-36-8
DC5088 WYE125132

WYE125132 is a highly potent, ATP-competitive, and specific mTOR kinase inhibitor

1144068-46-1
DC9514 Deforolimus Featured

Deforolimus(AP23573; MK-8669; Ridaforolimus) is a selective mTOR inhibitor with IC50 of 0.2 nM; while not classified as a prodrug, mTOR inhibition and FKBP12 binding is similar to rapamycin. IC50 value: 0.2 nM [1] Target: mTOR in vitro: Treatment of HT

572924-54-0
DC41010 PQR626 Featured

PQR626 is an orally available, and brain-penetrant mTOR inhibitor extracted from patent WO2017198346A1, compound example 44, has an IC50 of 5 nM for mTOR. PQR626 can be used for the research of neurological disorder.

1927857-98-4
DC44210 mTOR inhibitor-8

mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells.

2489196-70-3
DC44967 RMC-5552 Featured

RMC-5552 is a potent and selective inhibitor of mTORC1. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC50s of 0.14 nM and 0.48 nM, respectively. RMC-5552 has anti-cancer activity.

2382768-62-7
DC47252 RMC-6272

RMC-6272 (RM-006) is a bi-steric mTORC1-selective inhibitor. RMC-6272 exhibits potent and selective (> 10-fold) inhibition of mTORC1 over mTORC2. RMC-6272 shows improved inhibition of mTORC1 in comparison to Rapamycin, and induces more cell death in TSC2 null tumors.

2382769-46-0
DC47559 Dihydroevocarpine

Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity.

15266-35-0
DC47560 (32-Carbonyl)-RMC-5552

(32-Carbonyl)-RMC-5552 is a potent mTOR inhibitor. (32-Carbonyl)-RMC-5552 inhibits mTORC1 and mTORC2 substrate (p-P70S6K-(T389), p-4E-BP1-(T37/36), AND p-AKT1/2/3-(S473)) phosphorylation with pIC50s of > 9, >9 and between 8 and 9, respectively (patent WO2019212990A1, example 2).

2382768-55-8
DC47561 MHY-1685 Featured

MHY-1685, a novel mammalian target of rapamycin (mTOR) inhibitor, provides opportunities to improve hCSC-based myocardial regeneration.

27406-31-1
DC47913 RMC-4529

RMC-4529 has an IC50 value of 1.0 nM against p-4E-BP1-(T37/46) in mTOR kinase cellular assay.

2250059-27-7
DC48473 L-Leucine-13C6,15N

L-Leucine-13C6,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

202406-52-8
DC49290 L-Leucine-2-13C,15N

L-Leucine-2-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

285977-88-0
DC49291 L-Leucine-1-13C,15N

L-Leucine-1-13C,15N is the 13C- and 15N-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

80134-83-4
DC49293 L-Leucine-2-13C

L-Leucine-2-13C is the 13C-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

201612-66-0
DC49334 L-Leucine-18O2

L-Leucine-18O2 is the 18O-labeled L-Leucine. L-Leucine is an essential branched-chain amino acid (BCAA), which activates the mTOR signaling pathway.

73579-45-0
DC49377 RMC-4627

RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.

2250059-52-8
DC71016 CC214-2

CC214-2 is a potent and dual inhibitor of mTORC1/mTORC2. Mycobacterium tuberculosis modulates mammalian target of rapamycin (mTOR) signaling to impede autophagy. CC214-2 has the potential to shorten the duration of TB.

1228012-18-7
DC71229 PP30

PP30, a TORKinib, is a potent, selective, and ATP-competitive inhibitor of mTOR with an IC50 of 80 nM.

1092788-09-4
DC72910 CC214-1

CC214-1 is a potentially efficacious mTOR inhibitor that induces autophagy ,with an IC50 is 0.002 μM. CC214-1 proved to be useful as an in vitro tool compound for the exploration of mTOR kinase biology. CC214-1 can be used for Glioblastoma study.

1021920-32-0
DC74258 NV-5297

NV-5297 (NV5297) is a novel small molecule mTORC1 pathway activator, modulates the Sestrin2-Gator2 interaction and activates the mTORC1 pathway in vitro and in vivo.

2095886-40-9
<PrevNext >